ICD-10-CM Code Q87.83 for Bardet-Biedl Syndrome: What Manufacturers and Providers Must Do Next
For dates of service on or after October 1, 2023, providers have a dedicated ICD-10-CM diagnosis code for Bardet-Biedl syndrome (BBS): Q87.83. Before this update, BBS was reported under the unspecified catch-all code Q87.89 (Other specified congenital malformation syndromes, not elsewhere classified), which obscured the diagnosis and complicated treatment authorization, claims adjudication, and epidemiologic research.
Securing a dedicated diagnosis code for a rare disease is a meaningful milestone. It enables more accurate patient identification, supports payer authorization for BBS-specific therapies such as setmelanotide (IMCIVREE®, currently reported with HCPCS Level II code J3490), and strengthens the data available to clinicians and researchers studying a condition estimated to affect roughly 3,000 people in the United States and Canada. As with any new code, successful adoption depends on coordinated action across coding, clinical documentation, payer outreach, and provider education.
Common Implementation Mistakes Following a New ICD-10-CM Code
Even with Q87.83 effective since October 1, 2023, providers and manufacturers continue to make implementation mistakes. Avoid these common pitfalls:
Continuing to use Q87.89 instead of Q87.83: For dates of service on or after October 1, 2023, providers should report Q87.83 when the medical record supports a diagnosis of Bardet-Biedl syndrome. Continued use of Q87.89 misses the opportunity for accurate identification and may complicate claims adjudication for BBS-specific therapies.
Failing to document the clinical basis for the diagnosis: BBS is diagnosed clinically based on assessment of common features—including hyperphagia, obesity, retinal dystrophy, polydactyly, renal anomalies, hypogonadism, and cognitive impairment—along with patient history, family history, and genetics. The medical record should support the clinical diagnosis and document that a differential diagnosis was considered.
Not linking Q87.83 to BBS-specific therapies on the claim: Payers make payment determinations based on the patient's diagnosis and medical necessity aligned with approved indications. When a BBS-specific therapy such as setmelanotide is administered, link Q87.83 to the therapy on the claim to support medical necessity and reduce denials.
Assuming all payers have loaded the new ICD-10-CM code: Although ICD-10-CM updates take effect on October 1, payer claims system readiness can lag. Verify that major payers have loaded Q87.83 and that medical policy reflects the new code.
To realize the benefits of dedicated BBS coding—better patient identification, smoother claims adjudication, stronger research data—coding, clinical, market access, and patient services teams should align on documentation, payer communication, and provider education. The actions below outline a coordinated approach.
Critical Actions Following the Q87.83 Effective Date
To support accurate identification of BBS patients and effective use of BBS-specific therapies, manufacturers and providers should align on the following actions.
1. Confirm Effective Date and Code Descriptor
For dates of service on or after October 1, 2023, providers report ICD-10-CM code Q87.83 (Bardet-Biedl syndrome) for BBS diagnoses. The code replaces the use of Q87.89 (Other specified congenital malformation syndromes, not elsewhere classified) for BBS specifically. Confirm that EHR diagnosis pick-lists, problem-list templates, and coding workflows have been updated.
2. Educate Providers on the Clinical Basis for BBS Diagnosis
BBS is a rare genetic disorder of the primary cilia. Variants in BBS genes lead to ciliary dysfunction throughout the body, affecting the hypothalamus and impairing the MC4R pathway—the root cause of hyperphagia and subsequent obesity. Ciliary dysfunction can also affect neuronal development, the kidneys, reproductive system, eyes (rod cone dystrophy or retinitis pigmentosa), skeletal system (postaxial polydactyly, dental anomalies, brachydactyly, syndactyly), endocrine system (diabetes mellitus), and heart (congenital heart disease).
3. Support Provider Documentation of Differential Diagnosis
Other disorders may resemble BBS but have clinical differences. The medical record should document the clinical features supporting the BBS diagnosis, the differential diagnosis considered, and—where available—the genetic findings. Strong documentation supports both accurate coding and payer authorization of BBS-specific therapies.
4. Link Q87.83 to BBS-Specific Therapies on the Claim
When BBS-specific therapies such as setmelanotide (IMCIVREE®) are administered, link Q87.83 to the therapy on the claim to support medical necessity. Setmelanotide is currently reported with HCPCS Level II code J3490 (Unclassified drugs) until a specific code is established. The 2023 Obesity Medicine Association and American Academy of Pediatrics guidelines recommend prompt, comprehensive pharmacotherapy for BBS-associated obesity in adult and pediatric patients 6 years of age and older.
5. Verify Payer Claims System Loading and Coverage
Although ICD-10-CM updates take effect October 1, payer claims system readiness and medical policy updates can lag. For each major commercial payer and Medicare/Medicaid plan, confirm that Q87.83 has been loaded into claims systems, that medical policy for BBS-related therapies references the new code, and that prior authorization criteria are aligned with the approved indications.
6. Educate Patient Services and Reimbursement Hubs
For manufacturers of BBS-specific therapies, patient services and reimbursement hubs should be trained on the new ICD-10-CM code, the clinical features that support the diagnosis, and the documentation that payers typically request for authorization. Field reimbursement managers should be equipped to support provider offices through the transition.
7. Support Multidisciplinary Care Coordination
Because BBS is multisystemic, management requires a multidisciplinary approach across endocrinology, ophthalmology, nephrology, cardiology, genetics, and primary care. Accurate coding with Q87.83 across encounters supports better continuity of care, patient identification, and tracking of clinical outcomes over time.
8. Use the New Code to Strengthen Real-World Evidence
One of the rationales for the new code is improved epidemiologic research and outcomes tracking. Manufacturers and patient advocacy organizations can use claims data tied to Q87.83 to better understand disease prevalence, treatment patterns, healthcare costs, and unmet needs—supporting both clinical research and future coverage decisions.
Resources
Bardet-Biedl Syndrome Foundation — What is BBS?
NORD Rare Disease Database — Bardet-Biedl Syndrome
Disclaimer: The coding guidance and regulatory requirements described in this article are provided for general informational purposes. Coding logic and reimbursement mechanics vary by payer and setting. Hospitals and manufacturers should consult with compliance, legal, and coding counsel prior to implementing changes.
